Abreu Advogados, Portuguese law firm, successfully advised PME Investimentos, through its 200M CoInvestment Fund, in co-investment in LIMM Therapeutics.
The operation was coordinated by the partner and responsible for the M&A area at Abreu Advogados, Ana Sofia Batista, with the participation of professional partner, Rodrigo Formigal, and senior associate lawyer André Modesto Pinheiro.
The co-investors are 200M CoInvestment Fund and Seventure Partners.
Marco Fernandes, CEO of PME Investimentos, points out that “it is the first time that a life sciences technology developed at a portuguese university is able to attract international venture capital as specialized as Seventure Partners. 200M Fund is honored to support the entrepreneurs and scientific researchers from the Champalimaud Foundation, Henrique Veiga Fernandes and David Braga Malta and the future development of LiMM.”
The 200M Co InvestmentFund, managed by PME Investimentos – Sociedade de Investimento, is a matching fund that aims to foster co-investment in high growth starts ups in Portugal, with national or international private co-investors.
LiMM is a biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues, bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients. The company is the first harnessing the potential of neuronal regulation of Innate Lymphoid Cells (ILC) to tackle unmet medical needs.